Infantile Hemangioma - CHU Sainte-Justine - SAAC

More documents

Recommendations

Info

Timolol:Anything to Worry about?• 4-10x more potent than propranolol• Topical application so no first-pass metabolism• Reports of severe adverse events (AEs) withintraocular administration• Detectable in urine and in low levels in blood• Too soon to be confident re: AEs but none todate• Prudent to limit to 1-2 drops per treatmentMcMahon et al. Pediatr Dermatol 2012; 29:127-30
Page 1 and 2: Infantile Hemangiomas:Approach and
Page 3 and 4: Overview• Which hemangiomas need
Page 5 and 6: How do we decidewhich hemangiomasto
Page 7 and 8: Risk of Segmentals• Segmental hem
Page 9 and 10: Residual skin changes inuntreated h
Page 11 and 12: Very Early Growth:Birth 1 year 2yea
Page 13 and 14: Very Early Growth:Study usingparent
Page 15 and 16: Timing of Initiation of Treatment~1
Page 17 and 18: Reevaluationat age 3 to 4 years•
Page 19 and 20: Propranolol as RxLéauté-Labrèze
Page 21 and 22: Results of Systematic Review• Res
Page 23 and 24: Propranolol ConsensusGuidelinesDrol
Page 25 and 26: Monitoring - All Patients• The pe
Page 27 and 28: Caveat• This information is based
Page 29 and 30: What about TopicalBeta-Blockers?
Page 31: Topical Beta-Blockers:Experience in

Infantile Hemangioma - CHU Sainte-Justine - SAAC

Create successful ePaper yourself

Delete template?

Save as template?